Welcome to our dedicated page for Edgewise Therapeutics SEC filings (Ticker: EWTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Edgewise Therapeutics, Inc. (NASDAQ: EWTX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Edgewise is a clinical-stage biopharmaceutical company developing therapeutics for muscular dystrophies and serious cardiac conditions, and its filings offer detailed information on clinical progress, financial results, and corporate governance.
Investors can review current reports on Form 8-K that Edgewise files to announce material events, such as clinical data updates for sevasemten in Becker and Duchenne muscular dystrophies, progress in the EDG-7500 CIRRUS-HCM Phase 2 trial in hypertrophic cardiomyopathy, and initiation of Phase 1 studies for EDG-15400 in heart failure. Other 8-K filings describe financial results for specific quarters, appointments of new directors and executive officers, and equity-based compensation arrangements, including inducement grants under Nasdaq Listing Rule 5635(c)(4).
Through this page, users can also locate references to annual and quarterly reports (Forms 10-K and 10-Q) and related exhibits, where Edgewise discusses risk factors, liquidity, research and development expenses, and dependence on key product candidates such as sevasemten and EDG-7500. Disclosures frequently highlight that the company is clinical-stage, has not generated product revenue, and faces the typical uncertainties of drug development and regulatory approval.
Stock Titan enhances these filings with AI-powered summaries that explain the key points of lengthy documents, helping readers quickly understand clinical, financial, and governance information. Users can also track insider and equity-related disclosures reported in 8-K exhibits and other filings to see how leadership and directors are compensated and how the company structures its incentive plans.
Edgewise Therapeutics, Inc. is asking stockholders to vote at its in‑person annual meeting on June 4, 2026 in Boulder, Colorado. Stockholders of record as of April 9, 2026 may vote by internet, phone, mail or in person.
The board recommends voting for three Class II directors – Laura Brege, Badreddin Edris, Ph.D., and Jonathan Root, M.D. – for terms running until the 2029 annual meeting. It also recommends ratifying KPMG LLP as independent auditor for the year ending December 31, 2026 and approving, on an advisory basis, the compensation of the company’s named executive officers.
The proxy describes a largely independent, staggered board structure, outlines committee memberships, and details a non‑employee director compensation program with cash retainers and equity awards, including higher retainers and equity grant values effective April 1, 2026. It also highlights governance policies such as an Insider Trading Policy, hedging prohibitions and a Compensation Recovery Policy.
Edgewise Therapeutics, Inc. director Jonathan C. Fox received a grant of 339 shares of Common Stock as a stock award. The shares were acquired at no cash cost to him and increase his direct ownership to 24,514 shares following the transaction on April 1, 2026.
Edgewise Therapeutics, Inc. Chief Medical Officer Joanne M. Donovan reported an option exercise and related share sale. On April 1, 2026, she exercised stock options to acquire 28,662 shares of common stock at $7.08 per share, then sold 28,662 shares of common stock at an average price of $32.3109 per share. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 26, 2025. After these transactions, she directly holds 9,597 shares of Edgewise Therapeutics common stock.
Edgewise Therapeutics CMO Joanne M. Donovan exercised stock options to acquire 21,338 shares of common stock at an exercise price of $7.08 per share, then sold 21,338 shares in an open-market transaction at an average price of $32.1168 per share. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 26, 2025, meaning the trades were scheduled in advance. After these transactions, she directly holds 9,597 shares of common stock and 153,662 stock options that vest in equal monthly installments over 48 months beginning on September 17, 2023, and expire on August 17, 2033.
Edgewise Therapeutics CMO Joanne M. Donovan reported selling common stock in open-market transactions. On March 27, 2026, she sold a total of 16,358 shares of Edgewise Therapeutics, Inc. common stock in two sales at an average price of about $30.98 per share.
After these transactions, she directly holds 9,597 shares of common stock. Footnotes explain the shares sold were accumulated through multiple purchases under the company’s 2021 Employee Stock Purchase Plan between May 2022 and November 2024, including 594 shares purchased on November 17, 2025. The sales occurred across individual trades priced between $30.49 and $31.68.
EWTX reported a Form 144 notice listing planned sales of common stock tied to prior equity awards. The filing lists 50,000 shares from an exercise of stock options dated 03/27/2026, 9,623 shares from the Employee Stock Purchase Plan dated 05/15/2022, and 11,965 shares from restricted stock units dated 05/01/2024.
The form identifies the broker as Morgan Stanley Smith Barney LLC and indicates cash as the payment method for listed items. The filing does not show actual sales completed in the past three months in the excerpt provided.
Edgewise Therapeutics focuses on small-molecule drugs for serious muscle diseases, highlighting three main programs and a broad patent estate. The company targets rare neuromuscular disorders like Duchenne and Becker muscular dystrophy and cardiac diseases driven by sarcomere dysfunction.
Lead candidate sevasemten, an oral fast skeletal myosin inhibitor, is in multiple late-stage studies for Becker and Duchenne, with Phase 2 data showing significant reductions in muscle-damage biomarkers and stabilization of functional scores, and a pivotal Becker cohort (GRAND CANYON) fully enrolled. EDG-7500, a cardiac sarcomere modulator for hypertrophic cardiomyopathy, has Phase 2 data indicating large LVOT gradient and NT-proBNP reductions in both obstructive and non-obstructive HCM without meaningful declines in ejection fraction.
EDG-15400 is in Phase 1 for heart failure with preserved ejection fraction. Edgewise reports extensive global patent coverage on these assets, with key composition-of-matter patents extending into the 2040s. As of June 2025, non‑affiliate equity was valued at about $1.2 billion, and as of February 19, 2026, 107,270,521 common shares were outstanding.
Edgewise Therapeutics reported fourth-quarter and full-year 2025 results alongside major pipeline milestones in muscular dystrophy and cardiovascular programs. Cash, cash equivalents and marketable securities were $530.1 million as of December 31, 2025.
For Q4 2025, research and development expenses were $43.6 million, up from $37.5 million in the prior quarter, driven mainly by higher personnel costs and increased EDG-15400 and EDG-7500 clinical activity. General and administrative expenses rose to $12.4 million from $9.4 million.
The company reported a fourth-quarter net loss of $50.2 million, or $0.47 per share, compared with a net loss of $40.7 million, or $0.39 per share, in the preceding quarter. Edgewise highlighted upcoming catalysts, including GRAND CANYON pivotal data for sevasemten in Becker muscular dystrophy in Q4 2026, CIRRUS-HCM 12-week EDG-7500 data and Phase 1 EDG-15400 data in the first half of 2026.
Edgewise Therapeutics, Inc. reported a significant institutional holder in a Schedule 13G/A. Paradigm BioCapital Advisors LP and related entities disclosed beneficial ownership of 6,541,210 shares of Edgewise common stock, representing 6.2% of the outstanding shares as of December 31, 2025.
The filing states that Paradigm BioCapital International Fund Ltd. directly holds 5,778,924 shares, or 5.5% of the company. The ownership percentages are based on 105,868,434 shares of common stock outstanding as of October 31, 2025. The reporting group certifies that the shares are held on a passive basis, not to change or influence control of Edgewise.